CVS Subsidiary Omnicare Hires Alvarez & Marsal for Consulting Services
ByAinvest
Thursday, Sep 11, 2025 1:05 pm ET1min read
CVS--
The decision to hire Alvarez & Marsal follows a significant legal setback for Omnicare and its parent company, CVS Health. A federal judge recently denied their motion to overturn a drug-fraud suit, ordering Omnicare to pay $406.8 million in treble damages and $542 million in statutory penalties. CVS Health is liable for $164.8 million of these penalties [1].
The consulting firm will work with Omnicare to develop a plan to improve its performance and stabilize its operations. The company has faced increased operating expenses, with costs rising by $859 million, or 8.9% on a year-over-year basis for the six months that ended June 30, 2025 [2].
This latest development underscores the ongoing challenges faced by Omnicare and the broader healthcare industry. As the company seeks to navigate these difficulties, investors and stakeholders will be closely monitoring the progress made by Alvarez & Marsal and the strategies implemented to turn around Omnicare's performance.
Omnicare, a CVS Health subsidiary, has hired consulting firm Alvarez & Marsal to help stabilize the company. Omnicare provides pharmacy services to long-term care and post-acute facilities, as well as assisted living communities. The move comes as the company faces challenges in the industry. The consulting firm will help Omnicare address operational and financial issues, and develop a plan to improve its performance.
Omnicare, a subsidiary of CVS Health, has engaged consulting firm Alvarez & Marsal to address operational and financial issues, according to recent reports. The move comes amidst growing challenges within the industry, particularly for Omnicare, which provides pharmacy services to long-term care and post-acute facilities, as well as assisted living communities.The decision to hire Alvarez & Marsal follows a significant legal setback for Omnicare and its parent company, CVS Health. A federal judge recently denied their motion to overturn a drug-fraud suit, ordering Omnicare to pay $406.8 million in treble damages and $542 million in statutory penalties. CVS Health is liable for $164.8 million of these penalties [1].
The consulting firm will work with Omnicare to develop a plan to improve its performance and stabilize its operations. The company has faced increased operating expenses, with costs rising by $859 million, or 8.9% on a year-over-year basis for the six months that ended June 30, 2025 [2].
This latest development underscores the ongoing challenges faced by Omnicare and the broader healthcare industry. As the company seeks to navigate these difficulties, investors and stakeholders will be closely monitoring the progress made by Alvarez & Marsal and the strategies implemented to turn around Omnicare's performance.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet